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Value (SUV) was measured. The maximum SUV were compared with 
each histologic subtype and stage. 
Results: All 35 lesions showed various levels of increased FDG 
uptake. Table shows the relationship between histologic subtype and 
maximum SUV. With regard to stage, 10 patients were in stage I, 
8 were in stage II, 5 were in stage III, and 2 were in stage IVa. The 
maximum SUV were 4.0 ± 1.08 (range, 2.6-5.2) for stage I, 5.1 ± 2.07 
(range, 3.8-9.9) for stage II, 5.9 ± 2.57 (range, 3.5-8.9) for stage III, 
and 3.8 ± 1.27 (range, 2.9-4.7) for stage IVa. The differences in the 
maximum SUV between ﬁve histologic subtypes were statistically sig-
niﬁcant (p=0.000). On the other hand, no signiﬁcant differences were 
found between each stage.
Conclusions: Our results suggest that FDG-PET is useful for predict-
ing the histologic subtype in thymic epithelial tumors. Further studies 
are needed to evaluate other clinical usefulness of FDG-PET for thymic 
epithelial tumors.
  Maximum SUV
Histologic subtype No. of Patients Mean ± SD Range
A 4 3.3 ± 0.75 2.6-4.3
AB 8 3.9 ± 0.81 3.0-5.2
B1 4 4.7 ± 0.82 4.0-5.7
B2 3 5.1 ± 0.43 4.7-5.1
B3 2 9.1 ± 1.07 8.4-9.9
C 10 12.6 ± 4.43 5.8-19.9
Total 31 7.21 ± 4.72 2.6-19.9
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Background: There is little evidence to identify which patients being 
considered for surgical palliation of malignant pleural effusion (MPE) 
are at high risk of death or serious complications. We evaluated our 
experience to identify prognostic factors.
Methods: We reviewed 304 consecutive patients [188 female, median 
age 60 years (range 26-90)] who underwent 337 procedures for pallia-
tion of MPE over a 72 month period. Procedures performed included 
thoracoscopic talc pleurodesis 214, pleuroperitoneal shunt insertion 41, 
intercostal drainage and pleurodesis under local anaesthetic 40, pleural 
biopsy alone 30 and long term pleural drainage 10. The commonest 
malignancies were breast (32%), mesothelioma (24%), lung (15%) and 
ovary (9%). 
Results: Hospital mortality was 4.3%; complication rate 17% and 30 
day mortality 11.2%. Hypoalbuminaemia (p=0.003) and raised alanine 
transaminase (ALT) (p=0.004) were associated with increased hospital 
mortality on univariate analysis. On multivariate analysis hypoalbu-
minaemia maintained signiﬁcance (p=0.04). Post operative complica-
tions were associated with a preoperative diagnosis of malignancy 
(p=0.03) on univariate analysis. No factor maintained signiﬁcance 
on multivariate analysis. Thirty day mortality was associated with 
preoperative diagnosis of malignancy (p=0.028), short duration of 
symptoms (p=0.042), hypoxaemia (p=0.006), leucocytosis (p<0.001), 
hypoalbuminaemia (p<0.001), raised ALT (p<0.001) and poor perfor-
mance status (p=0.014) on univariate analysis. Leucocytosis (p=0.014), 
hypoalbumiaemia (p=0.001) and raised ALT (p=0.032) maintained 
signiﬁcance on multivariate analysis.
  Hospital Mortality
30-day  
Mortality
Complications
WCC >12 4 of 55 (7.3%) 15 of 52 (29%) 7 of 55 (13%)
 <12 11 of 277 (3.9%) 23 of 248 (9.3%) 59 of 277 (21%)
Albumin <35 15 of 222 (6.8%) 37 of 197 (19%) 44 of 222 (20%)
 >35 0 of 109 (0%) 1 of 102 (0.98%) 22 of 109 (21%)
ALT <41 8 of 269 (2.9%) 23 of 241 (9.5%) 50 of 269 (18%)
 >41 7 of 51 (14%) 15 of 48 (31%) 11 of 51 (21%)
Conclusions: Hypoalbuminaemia is a marker of generalized physi-
ological impairment; it is associated with increased mortality both in 
hospital and at 30 days. Its presence should inﬂuence risk assessment, 
treatment decisions and discussions with the patient.
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Background: Thymic epithelial tumors (TETs), the most common 
tumor of the anterior mediastinum, are epithelial neoplasms of the 
thymus with a wide spectrum of morphologic features. 
Methods: We retrospectively analyzed clinical features of TET and 
the correlation of WHO histologic classiﬁcation and Masaoka staging 
system with different treatment modalities in 195 patients, from 1995 
to 2005. 
Results: According to the Masaoka’s staging system, there were 78 
(40.0 %) patients with stage I, 38 (19.5%) with stage II, 41 (21.0%) 
with stage III, 38 (19.5%) with stage IV. All patients were re-classi-
ﬁed according to the WHO criteria as follows: Type A (n=9, 4.6%), 
AB (n=37, 18.9%), B1 (n=29, 14.8%), B2 (n=48, 24.6%), B3 (n=40, 
20.5%), C (n=32, 16.4%). There was a fairly good correlation between 
Masaoka staging and WHO histotype (P<0.05). However, in multivari-
ate analysis, the tumor stage and WHO histotype were two independent 
factors separately for predicting overall survival (P <0.001, P <0.001, 
respectively). Thus, both Masaoka stage and WHO histotype should 
be considered in risk stratiﬁcation of therapy for TET patients. Patients 
with completely resected type B2, B3 and C and adjuvant radiotherapy 
(n=57) had more favorable disease-free and overall survival as com-
pared with those without adjuvant treatment (n=20) (P=0.015, 0.015, 
respectively). Given that the predominant sites of recurrence after 
surgery was pleura/pericardium and lung, and the fact that complete re-
section was a signiﬁcant inﬂuential factor for survival at log-rank test, 
an active investigation of newer treatment strategies such as neoadju-
vant treatment to improve the resectability and development of optimal 
adjuvant treatment modality is a high priority especially for those with 
high-risk for recurrence or in patients with advanced stage disease.
Conclusions: Though there was a clear association between the two 
systems the Masaoka stage and WHO histotype were two independent 
prognostic factors for survival. Despite of some discordance between 
